Assessment of Efficacy, Reliability, Side Effects and Patient Compliance of Entecavir in Turkish Patients with Nukleos(t)ide Analogues Naive Chronic Hepatitis B

Abstract

Objectives: This study aimed to assess the entecavir (ENT) in Turkish patients with nukleos(t)ide analogues (NA) naivechronic hepatitis B (CHB).Methods: The data in this study were collected retrospectively. The rates of compliance, biological, virological, andserological responses, and drug resistance and the frequency of ENT-related side effects were determined.Results: A total of 40 patients were enrolled in this study. The rates of virological response, biochemical response inHBeAg (-) patients were 100% and 96.6%, respectively. There was no HBsAg loss in HBeAg (-) patients. The rates ofvirological response, biochemical response, serological response, and HBsAg loss in HBeAg (+) patients were 100%,90%, 70%, and 10% respectively. The rates of virological response and biochemical response in both HBeAg (-) and (+)patients were 100% and 95%, respectively. Complete response was detected in only one of 40 patients (2.5%) at the96th week of treatment. The most ENT-related side effects were fatigue. Only two patients had mild renal impairment,whereas moderate or severe renal impairment was not detected.Conclusion: The treatment of ENT can be safely used as an effective first-line drug in adult Turkish patients with NAnaiveCHB. Patients should be followed up more closely in terms of renal function during treatment.